Serina Therapeutics appoints Steven Ledger as permanent CEO; base $450k, options grant

Serina Therapeutics, Inc.

Steven Ledger, interim CEO since March 2024, appointed permanent CEO effective Sept 8, 2024.
Annual base salary $450,000, increasing to $500,000 upon strategic goal; bonus up to 50% of base.
Received 501,851 stock options; 75% time-vested over 4 years, 25% performance-based.
Severance: 12 months base plus prorated bonus (min half) if terminated without cause.
Ledger has 35+ years experience; retains board seat.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Steven Ledger

Chief Executive Officer

SER · Serina Therapeutics, Inc.

Effective: 2024-09-08
Filed: September 12, 2024, 7:59 PM ET

On September 8, 2024, the Board of Directors (the “Board”) of Serina Therapeutics, Inc. (the “Company”) appointed Steven Ledger, the current Interim Chief Executive Officer of the Company, to be the Company’s Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Steven Ledger was appointed as Chief Executive Officer at Serina Therapeutics, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On September 8, 2024, the Board of Directors (the “Board”) of Serina Therapeutics, Inc. (the “Company”) appointed Steven Ledger, the current Interim Chief Executive Officer of the Company, to be the Company’s Chief Executive Officer.

View on SEC.gov

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-036080

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.